Literature DB >> 20358691

Drugs and pharmaceuticals: management of intoxication and antidotes.

Silas W Smith1.   

Abstract

The treatment of patients poisoned with drugs and pharmaceuticals can be quite challenging. Diverse exposure circumstances, varied clinical presentations, unique patient-specific factors, and inconsistent diagnostic and therapeutic infrastructure support, coupled with relatively few definitive antidotes, may complicate evaluation and management. The historical approach to poisoned patients (patient arousal, toxin elimination, and toxin identification) has given way to rigorous attention to the fundamental aspects of basic life support--airway management, oxygenation and ventilation, circulatory competence, thermoregulation, and substrate availability. Selected patients may benefit from methods to alter toxin pharmacokinetics to minimize systemic, target organ, or tissue compartment exposure (either by decreasing absorption or increasing elimination). These may include syrup of ipecac, orogastric lavage, activated single- or multi-dose charcoal, whole bowel irrigation, endoscopy and surgery, urinary alkalinization, saline diuresis, or extracorporeal methods (hemodialysis, charcoal hemoperfusion, continuous venovenous hemofiltration, and exchange transfusion). Pharmaceutical adjuncts and antidotes may be useful in toxicant-induced hyperthermias. In the context of analgesic, anti-inflammatory, anticholinergic, anticonvulsant, antihyperglycemic, antimicrobial, antineoplastic, cardiovascular, opioid, or sedative-hypnotic agents overdose, N-acetylcysteine, physostigmine, L-carnitine, dextrose, octreotide, pyridoxine, dexrazoxane, leucovorin, glucarpidase, atropine, calcium, digoxin-specific antibody fragments, glucagon, high-dose insulin euglycemia therapy, lipid emulsion, magnesium, sodium bicarbonate, naloxone, and flumazenil are specifically reviewed. In summary, patients generally benefit from aggressive support of vital functions, careful history and physical examination, specific laboratory analyses, a thoughtful consideration of the risks and benefits of decontamination and enhanced elimination, and the use of specific antidotes where warranted. Data supporting antidotes effectiveness vary considerably. Clinicians are encouraged to utilize consultation with regional poison centers or those with toxicology training to assist with diagnosis, management, and administration of antidotes, particularly in unfamiliar cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20358691      PMCID: PMC7123602          DOI: 10.1007/978-3-7643-8338-1_12

Source DB:  PubMed          Journal:  EXS        ISSN: 1023-294X


  459 in total

1.  HEAT STROKE: CLINICAL AND CHEMICAL OBSERVATIONS ON 44 CASES.

Authors:  E B Ferris; M A Blankenhorn; H W Robinson; G E Cullen
Journal:  J Clin Invest       Date:  1938-05       Impact factor: 14.808

2.  Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid).

Authors:  L M MEYER; F R MILLER; M J ROWEN; G BOCK; J RUTZKY
Journal:  Acta Haematol       Date:  1950-09       Impact factor: 2.195

Review 3.  Digoxin-specific antibody fragments: how much and when?

Authors:  D Nicholas Bateman
Journal:  Toxicol Rev       Date:  2004

4.  Esophageal laceration and charcoal mediastinum complicating gastric lavage.

Authors:  E M Caravati; H H Knight; M S Linscott; J C Stringham
Journal:  J Emerg Med       Date:  2001-04       Impact factor: 1.484

5.  Home syrup of ipecac use does not reduce emergency department use or improve outcome.

Authors:  G R Bond
Journal:  Pediatrics       Date:  2003-11       Impact factor: 7.124

Review 6.  Valproate-associated hyperammonemic encephalopathy.

Authors:  Jim Wadzinski; Ronald Franks; David Roane; Max Bayard
Journal:  J Am Board Fam Med       Date:  2007 Sep-Oct       Impact factor: 2.657

7.  Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy.

Authors:  Robert C Kane; W David McGuinn; Ramzi Dagher; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2008-04

8.  A case of valproate-associated hepatotoxicity treated with L-carnitine.

Authors:  Auxiliadora Romero-Falcón; Eva de la Santa-Belda; Rosa García-Contreras; José M. Varela
Journal:  Eur J Intern Med       Date:  2003-08       Impact factor: 4.487

9.  Sedative and ventilatory effects of midazolam infusion: effect of flumazenil reversal.

Authors:  C T Mora; M Torjman; P F White
Journal:  Can J Anaesth       Date:  1995-08       Impact factor: 5.063

10.  Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study.

Authors:  Shaun L Greene; Indika Gawarammana; David M Wood; Alison L Jones; Paul I Dargan
Journal:  Intensive Care Med       Date:  2007-07-11       Impact factor: 17.440

View more
  3 in total

1.  The role of iNOS inhibitors on lung injury induced by gastrointestinal decontamination agents aspiration.

Authors:  Ahmet Güzel; Aygül Güzel; Mithat Günaydin; Hasan Alaçam; Osman Saliş; M Sükrü Paksu; Naci Murat; Ayhan Gacar; Tolga Güvenç
Journal:  J Mol Histol       Date:  2012-02-29       Impact factor: 2.611

2.  Gastrointestinal decontamination in the acutely poisoned patient.

Authors:  Timothy E Albertson; Kelly P Owen; Mark E Sutter; Andrew L Chan
Journal:  Int J Emerg Med       Date:  2011-10-12

Review 3.  The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway.

Authors:  Giuseppe Caruso; Anna Privitera; Barbara Moura Antunes; Giuseppe Lazzarino; Susan Marie Lunte; Giancarlo Aldini; Filippo Caraci
Journal:  Molecules       Date:  2022-07-12       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.